Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Krystal Biotech, Inc.

35 indications, side-by-side phase, drug & LoA

$317.97

-3.05 (-0.95%)

C 46Pipeline Score Richly Valued Biotech · Commercial
Market Cap
8.83 B
EPS
7.74
P/E Ratio
40.03 $
Value Trade
72.18 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    116.36 M

  • R&D Expenses

    15.33 M

  • Operating CF

    80.38 M

  • Total Assets

    1.40 B

  • Total Liabilities

    120.24 M

  • Equity

    1.28 B

  • D/E Ratio

    12,345

-4.11 %
Week
8.82 %
1 Month
14.51 %
3 Month
46.75 %
6 Month
337.03 %
5 Year
2,751.9 %
All Time
Cash Data
Profitable

  • Cash Position

    823.40 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 4, 2026
Overview
Volume
313.52 K
52 Week Range
123.03 - 319.48
% held by Insiders
12.56 %
% held by Institutions
96.01 %
Enterprise Value
8.01 B
Total Shares
29.44 M
Short %
13.15 %
Float Shares
23.93 M
Company Description
HQ: 2100 WHARTON STREET, PITTSBURG...
Employees:295
https://www.krystalbio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1 interim results example
KB408 Alpha-1 antitrypsin deficiency (AATD) — adult patients with Pi*ZZ or Pi*ZNull genotypes, inhaled gene therapy
Phase 1
—
-
-
KB408 Alpha-1 antitrypsin deficiency (AATD) — adult patients with Pi*ZZ or Pi*ZNull genotypes, inhaled gene therapy
Phase 1
—
-
-
KB408 Alpha-1 antitrypsin deficiency (AATD) — adult patients with Pi*ZZ or Pi*ZNull genotypes, inhaled gene therapy
Phase 1
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C46
Pipeline Score
$41M
Pipeline Value
Richly Valued
Valuation Signal
8
Drugs Scored
0.0x
rNPV / MCap
Top 64%
Small Cap
(rank 327 of 905)
Percentile Rank
Krystal Biotech, Inc. carries a moderate pipeline score (46/100), with $63M risk-adjusted pipeline value, led by KB707 in Cancer (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
KB707
Monoclonal antibody		CancerPhase 1NCT0597049717% $42M RECRUITING 240 STALLED C (43) Jul 1, 2027ELEVATED_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
KB803
corneal abrasions,dystrophic epidermolysis bullosa
Phase 3
2025-06-24
KB803
corneal abrasions,dystrophic epidermolysis bullosa
Phase 3
2025-06-24
KB803
corneal abrasions,dystrophic epidermolysis bullosa
Phase 3
2025-06-24
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in KRYS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
KRYS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KRYS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KRYS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
KRYS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
KRYS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Krystal Biotech, Inc. (KRYS) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How KRYS ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Genodermatoses #1 of 4 PHASE 3 KB803
ABEO CSTL ARGX
—0.87 LEADER
Skin Aging #1 of 2 PHASE 1 KB304 + 0.9% Normal Saline
IPSC
$82.8B 0.92 LEADER
Cystic Fibrosis #6 of 7 PHASE 1 KB407
VRTX SION PHGE
$13.49B 0.76 FOLLOWER
Rare Genetic Disorders #10 of 61 PHASE 3 KB803
BMRN ASND NVS
—0.86 CONTENDER
Melanoma #33 of 52 PHASE 1 KB707 + Opdualag + KEYTRUDA
MRK BMY REGN
$10.5B 0.77 FOLLOWER
Lung Cancer #49 of 79 PHASE 1 KB707 + Pembrolizumab + Chemotherapy + Docetaxel
MRK GILD AMGN
$28.1B 0.76 FOLLOWER
Non-Small Cell Lung Cancer #56 of 88 PHASE 1 KB707 + Pembrolizumab + Chemotherapy + Docetaxel
MRK AMGN AZN
$28.1B 0.76 FOLLOWER